N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-2-[(3S)-3-isopropyl-5-oxo-4-propylpiperazin-1-yl]acetamide | 488847-22-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-2-[(3S)-3-isopropyl-5-oxo-4-propylpiperazin-1-yl]acetamide
• 英文别名: N-[(2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-[(3-iodophenyl)methylamino]butan-2-yl]-2-[(5S)-3-oxo-5-propan-2-yl-4-propylpiperazin-1-yl]acetamide
• CAS: 488847-22-9
• 化学式: C₂₉H₃₉F₂IN₄O₃
• 分子量: 656.555
• InChiKey: AYYNJRCVLREOTD-OYUWMTPXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  39
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  84.9
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds
  申请人：——

  公开号：US20030109559A1

  公开（公告）日：2003-06-12

  Disclosed are compounds of the formula (I): 1 useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.

  揭示了以下式（I）的化合物，用于治疗阿尔茨海默病和其他类似疾病。这些化合物包括抑制β-分泌酶酶的抑制剂，可用于治疗阿尔茨海默病和其他在哺乳动物体内沉积Aβ肽的疾病。本发明的化合物在制药组合物和治疗方法中有用，可减少Aβ肽的形成。
• N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS
  申请人：Elan Pharmaceuticals, Inc.

  公开号：EP1409450A1

  公开（公告）日：2004-04-21
• [EN] N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS<br/>[FR] COMPOSES DE N-(3-AMINO-2-HYDROXY-PROPYL) ALKYLAMIDE SUBSTITUES
  申请人：ELAN PHARM INC

  公开号：WO2003006423A1

  公开（公告）日：2003-01-23

  Disclosed are compounds of the formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the betasecretase enzyme that are useful in the treatment of Alzeheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.